Johoku-Cilnidipine trial of renal function and blood pressure for clinical evaluation.
- Conditions
- Essential Hypertension
- Registration Number
- JPRN-UMIN000003956
- Lead Sponsor
- Teikyo University
- Brief Summary
This study assessed the urinary albumin/creatinine ratio and uric acid metabolism in 70 hypertensive patients with CKD in whom the urinary albumin/creatinine ratio had remained  30 mg/g under the treatment of L-type calcium channel blocker amlodipine. Three months after switching to N/L-type calcium channel blocker cilnidipine, blood pressure did not change. However, urinary albumin/creatinine ratio significantly decreased by cilnidipine. Serum uric acid levels showed no significant change. In cases where uric acid production had been high (urinary uric acid/creatinine ratio  0.5), the urinary uric acid/creatinine ratio decreased significantly after cilnidipine treatment, suggesting that cilnidipine can suppress excessive uric acid formation. These results suggest that switching from amlodipine to cilnidipine resulted in a significant reduction in urinary albumin/creatinine ratio as well as significant reduction in uric acid production. Thus cilnidipine is more useful than amlodipine in improving albuminuria and uric acid metabolism in hypertensive patients with CKD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 150
Not provided
Following patients will be excluded from this study. 1.Pregnant women or suspected of being pregnant. 2.Severe liver dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Office blood pressure 2.Home blood pressure 3.Urinary albumin excretion
- Secondary Outcome Measures
Name Time Method 1.Heart rate 2.Serum uric acid 3.Adverse events